Find Clinical Trials | Cedars-Sinai

141 results found

Breast, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Liver ...

Teva, TV56278-ONC-10203, Ph1a/1b, Open Label, Locally Adv or Metastatic Solid Tumors, TEV-56278

Objectives Primary To characterize the safety and tolerability of TEV-56278 in the trial population To determine a RP2D Secondary To characterize the serum pharmacokinetics of TEV-56278 in the trial population To evaluate the antitumor activity of ...

Breast, Cervix, Esophagus, Kidney, Liver, Lung, Melanoma, Other Female Genital ...

Corbus, CRB-601-01, PhI/II, open-label, various solid tumors, CRB-601

Primary Objective: Part A: To evaluate the safety and tolerability and determine the MTD and PADR for CRB-601 administered as a monotherapy in patients with select relapsed/refractory solid tumors who have progressed after at least one ...

Ovary

Olaparib With or Without Bevacizumab in BRCA 1/2 Mutated or Homologous Recombination Deficient Ovarian Cancer

This study focuses on people with ovarian cancer who have tested positive for BRCA1/2 mutation (change or defect in the BRCA gene) or homologous recombination deficiency (when the body cannot repair breaks in DNA). The ...

Breast

Low-Dose Tamoxifen in Low-Risk, Early-Stage Breast Cancer

Hormone receptor-positive breast cancer is the most common type of breast cancer, and 5+ years of hormone therapy is the mainstay of the treatment. However, many patients experience side effects from the medications, and some ...

Lung

Amgen, 20230153, Ph 2, randomized, open-label, NSCLC, AMG193

Primary Objective: To characterize safety and efficacy of 2 dose levels of AMG 193 by investigator.